Subscribe Sign In Register

Premium

How ValueAct Shook Off Its Big Loss from Valeant

The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.

By Stephen Taub Stephen Taub
January 6, 2017
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg

Ron Antonelli/Bloomberg

Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Pharmaceutical Valueact Jeff Ubben Valiant
Related
Michael Nagle/Bloomberg
Portfolio
Hedge Fund Activist Jeff Ubben Asks SEC to Mandate Carbon Pricing Disclosures
Michelle Celarier
September 14, 2021
Brent Lewin/Bloomberg
Corner Office
Antitrust Enforcement Is Back, and the Aon-Willis Towers Watson Deal Is Just the Beginning
Alicia McElhaney
July 27, 2021
Aerial view of tractor as dragging a sowing machine over agricultural field, farmland
Sponsored
After a Mixed 2024 for U.S. Agriculture, What’s Next?